PMID- 2472482
OWN - NLM
STAT- MEDLINE
DCOM- 19890810
LR  - 20131121
IS  - 0022-3565 (Print)
IS  - 0022-3565 (Linking)
VI  - 244
IP  - 3
DP  - 1988 Mar
TI  - Effects of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine 
      isomers on central serotonergic, dopaminergic and nigral neurotensin systems of 
      the rat.
PG  - 977-82
AB  - This study demonstrates that the isomers of 3,4-methylenedioxyamphetamine (MDA) 
      and 3,4-methylenedioxymethamphetamine (MDMA) are different in their ability to 
      induce changes in serotonergic parameters and nigral concentrations of 
      neurotensin-like immunoreactivity. With five successive doses (3.5 mg/kg) the 
      d-MDA isomer was more potent than the l-MDA in its ability to decrease the 
      concentrations of serotonin in the frontal cortex and hippocampus. The same 
      difference occurred in the ability to decrease the hippocampal activity of 
      tryptophan hydroxylase as well as the hippocampal and neostriatal 
      5-hydroxyindoleacetic acid concentrations. However, both isomers of MDMA were 
      equipotent in their ability to decrease serotonergic parameters in the brain 
      areas examined. When the doses were increased to 5 and 10 mg/kg, both isomers of 
      MDA were equipotent in their effects on the serotonin system, whereas the l-MDMA 
      was significantly less potent than its d isomeric counterpart in causing a 
      decrease in serotonergic parameters of the different brain areas. In contrast, 
      treatments with any of the isomers appeared to have a minimal impact on 
      neostriatal dopaminergic parameters. However, treatment with MDA or MDMA caused 
      increases in the nigral concentrations of neurotensin, with the d isomer of both 
      compounds having substantially greater effects on this neuropeptide system. These 
      increases are suspected to result from drug-released dopamine. This study 
      demonstrates that at selected doses, the d isomers of MDA and MDMA are more 
      potent than their l forms in affecting neurochemical systems, whereas high doses 
      of either isomer of MDA share a common ability to induce changes in the 
      serotonergic system that are likely associated with neuronal damage.
FAU - Johnson, M
AU  - Johnson M
AD  - Department of Pharmacology and Toxicology, University of Utah, Salt Lake City 
      84112.
FAU - Letter, A A
AU  - Letter AA
FAU - Merchant, K
AU  - Merchant K
FAU - Hanson, G R
AU  - Hanson GR
FAU - Gibb, J W
AU  - Gibb JW
LA  - eng
GR  - DA 00869/DA/NIDA NIH HHS/United States
GR  - DA 04222/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Pharmacol Exp Ther
JT  - The Journal of pharmacology and experimental therapeutics
JID - 0376362
RN  - 0 (Amphetamines)
RN  - 333DO1RDJY (Serotonin)
RN  - 39379-15-2 (Neurotensin)
RN  - 4764-17-4 (3,4-Methylenedioxyamphetamine)
RN  - 54-16-0 (Hydroxyindoleacetic Acid)
RN  - EC 1.14.16.4 (Tryptophan Hydroxylase)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - VTD58H1Z2X (Dopamine)
SB  - IM
MH  - 3,4-Methylenedioxyamphetamine/analogs & derivatives/*pharmacology
MH  - Amphetamines/*pharmacology
MH  - Animals
MH  - Brain Chemistry/*drug effects
MH  - Dopamine/*analysis/metabolism
MH  - Hydroxyindoleacetic Acid/analysis
MH  - Male
MH  - N-Methyl-3,4-methylenedioxyamphetamine
MH  - Neurotensin/*analysis
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Serotonin/*analysis
MH  - Stereoisomerism
MH  - Substantia Nigra/analysis/*drug effects
MH  - Tryptophan Hydroxylase/analysis
EDAT- 1988/03/01 00:00
MHDA- 1988/03/01 00:01
CRDT- 1988/03/01 00:00
PHST- 1988/03/01 00:00 [pubmed]
PHST- 1988/03/01 00:01 [medline]
PHST- 1988/03/01 00:00 [entrez]
PST - ppublish
SO  - J Pharmacol Exp Ther. 1988 Mar;244(3):977-82.